These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

656 related articles for article (PubMed ID: 34022150)

  • 1. Safety and efficacy of rituximab in patients with diffuse large B-cell lymphoma in Malawi: a prospective, single-arm, non-randomised phase 1/2 clinical trial.
    Kimani S; Painschab MS; Kaimila B; Kasonkanji E; Zuze T; Tomoka T; Mulenga M; Nyasosela R; Chikasema M; Mtangwanika A; Chawinga M; Mhango W; Nicholas S; Chimzimu F; Kampani C; Krysiak R; Lilly A; Randall C; Seguin R; Westmoreland KD; Montgomery ND; Fedoriw Y; Gopal S
    Lancet Glob Health; 2021 Jul; 9(7):e1008-e1016. PubMed ID: 34022150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trial.
    Johnston PB; LaPlant B; McPhail E; Habermann TM; Inwards DJ; Micallef IN; Colgan JP; Nowakowski GS; Ansell SM; Witzig TE
    Lancet Haematol; 2016 Jul; 3(7):e309-16. PubMed ID: 27374464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial.
    Poeschel V; Held G; Ziepert M; Witzens-Harig M; Holte H; Thurner L; Borchmann P; Viardot A; Soekler M; Keller U; Schmidt C; Truemper L; Mahlberg R; Marks R; Hoeffkes HG; Metzner B; Dierlamm J; Frickhofen N; Haenel M; Neubauer A; Kneba M; Merli F; Tucci A; de Nully Brown P; Federico M; Lengfelder E; di Rocco A; Trappe R; Rosenwald A; Berdel C; Maisenhoelder M; Shpilberg O; Amam J; Christofyllakis K; Hartmann F; Murawski N; Stilgenbauer S; Nickelsen M; Wulf G; Glass B; Schmitz N; Altmann B; Loeffler M; Pfreundschuh M; ;
    Lancet; 2019 Dec; 394(10216):2271-2281. PubMed ID: 31868632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
    Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
    Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial.
    Davies A; Cummin TE; Barrans S; Maishman T; Mamot C; Novak U; Caddy J; Stanton L; Kazmi-Stokes S; McMillan A; Fields P; Pocock C; Collins GP; Stephens R; Cucco F; Clipson A; Sha C; Tooze R; Care MA; Griffiths G; Du MQ; Westhead DR; Burton C; Johnson PWM
    Lancet Oncol; 2019 May; 20(5):649-662. PubMed ID: 30948276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
    Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
    Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial.
    Ladetto M; Cortelazzo S; Ferrero S; Evangelista A; Mian M; Tavarozzi R; Zanni M; Cavallo F; Di Rocco A; Stefoni V; Pagani C; Re A; Chiappella A; Balzarotti M; Zilioli VR; Gomes da Silva M; Arcaini L; Molinari AL; Ballerini F; Ferreri AJM; Puccini B; Benedetti F; Stefani PM; Narni F; Casaroli I; Stelitano C; Ciccone G; Vitolo U; Martelli M
    Lancet Haematol; 2021 Jan; 8(1):e34-e44. PubMed ID: 33357480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group.
    Peyrade F; Bologna S; Delwail V; Emile JF; Pascal L; Fermé C; Schiano JM; Coiffier B; Corront B; Farhat H; Fruchart C; Ghesquieres H; Macro M; Tilly H; Choufi B; Delarue R; Fitoussi O; Gabarre J; Haioun C; Jardin F
    Lancet Haematol; 2017 Jan; 4(1):e46-e55. PubMed ID: 28041583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study.
    Robak T; Jin J; Pylypenko H; Verhoef G; Siritanaratkul N; Drach J; Raderer M; Mayer J; Pereira J; Tumyan G; Okamoto R; Nakahara S; Hu P; Appiani C; Nemat S; Cavalli F;
    Lancet Oncol; 2018 Nov; 19(11):1449-1458. PubMed ID: 30348538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
    Cunningham D; Hawkes EA; Jack A; Qian W; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford JA; McMillan A; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
    Lancet; 2013 May; 381(9880):1817-26. PubMed ID: 23615461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial.
    Vitolo U; Chiappella A; Franceschetti S; Carella AM; Baldi I; Inghirami G; Spina M; Pavone V; Ladetto M; Liberati AM; Molinari AL; Zinzani P; Salvi F; Fattori PP; Zaccaria A; Dreyling M; Botto B; Castellino A; Congiu A; Gaudiano M; Zanni M; Ciccone G; Gaidano G; Rossi G;
    Lancet Oncol; 2014 Jun; 15(7):730-7. PubMed ID: 24831981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. R-CHOP, radioimmunotherapy, and maintenance rituximab in untreated follicular lymphoma (SWOG S0801): a single-arm, phase 2, multicentre study.
    Barr PM; Li H; Burack WR; LeBlanc M; Smith SM; Gopal AK; Floyd JD; Persky DO; Press OW; Fisher RI; Friedberg JW
    Lancet Haematol; 2018 Mar; 5(3):e102-e108. PubMed ID: 29396094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): a multicentre, single-arm, phase 2 trial.
    Shimada K; Yamaguchi M; Atsuta Y; Matsue K; Sato K; Kusumoto S; Nagai H; Takizawa J; Fukuhara N; Nagafuji K; Miyazaki K; Ohtsuka E; Okamoto M; Sugita Y; Uchida T; Kayukawa S; Wake A; Ennishi D; Kondo Y; Izumi T; Kin Y; Tsukasaki K; Hashimoto D; Yuge M; Yanagisawa A; Kuwatsuka Y; Shimada S; Masaki Y; Niitsu N; Kiyoi H; Suzuki R; Tokunaga T; Nakamura S; Kinoshita T
    Lancet Oncol; 2020 Apr; 21(4):593-602. PubMed ID: 32171071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study.
    Dunleavy K; Fanale MA; Abramson JS; Noy A; Caimi PF; Pittaluga S; Parekh S; Lacasce A; Hayslip JW; Jagadeesh D; Nagpal S; Lechowicz MJ; Gaur R; Lucas A; Melani C; Roschewski M; Steinberg SM; Jaffe ES; Kahl B; Friedberg JW; Little RF; Bartlett NL; Wilson WH
    Lancet Haematol; 2018 Dec; 5(12):e609-e617. PubMed ID: 30501868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon alfa-2b in patients with low-grade lymphomatoid granulomatosis and chemotherapy with DA-EPOCH-R in patients with high-grade lymphomatoid granulomatosis: an open-label, single-centre, phase 2 trial.
    Melani C; Dowdell K; Pittaluga S; Dunleavy K; Roschewski M; Song JY; Calattini S; Kawada JI; Price DA; Chattopadhyay PK; Roederer M; Lucas AN; Steinberg SM; Jaffe ES; Cohen JI; Wilson WH
    Lancet Haematol; 2023 May; 10(5):e346-e358. PubMed ID: 37011643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Venetoclax with dose-adjusted EPOCH-R as initial therapy for patients with aggressive B-cell lymphoma: a single-arm, multicentre, phase 1 study.
    Rutherford SC; Abramson JS; Bartlett NL; Barta SK; Khan N; Joyce R; Maddocks K; Ali-Shaw T; Senese S; Yuan Y; Westin J; Leonard JP
    Lancet Haematol; 2021 Nov; 8(11):e818-e827. PubMed ID: 34634256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Positron emission tomography-adapted therapy in low-risk diffuse large B-cell lymphoma: results of a randomized, phase III, non-inferiority trial.
    Shi Q; He Y; Yi HM; Mu RJ; Jiang XF; Fu D; Dong L; Qin W; Xu PP; Cheng S; Song Q; Chen SJ; Wang L; Zhao WL
    Cancer Commun (Lond); 2023 Aug; 43(8):896-908. PubMed ID: 37403255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.
    Rummel MJ; Niederle N; Maschmeyer G; Banat GA; von Grünhagen U; Losem C; Kofahl-Krause D; Heil G; Welslau M; Balser C; Kaiser U; Weidmann E; Dürk H; Ballo H; Stauch M; Roller F; Barth J; Hoelzer D; Hinke A; Brugger W;
    Lancet; 2013 Apr; 381(9873):1203-10. PubMed ID: 23433739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial.
    Peyrade F; Jardin F; Thieblemont C; Thyss A; Emile JF; Castaigne S; Coiffier B; Haioun C; Bologna S; Fitoussi O; Lepeu G; Fruchart C; Bordessoule D; Blanc M; Delarue R; Janvier M; Salles B; André M; Fournier M; Gaulard P; Tilly H;
    Lancet Oncol; 2011 May; 12(5):460-8. PubMed ID: 21482186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of best supportive care, CHOP, or R-CHOP for treatment of diffuse large B-cell lymphoma in Malawi: a cost-effectiveness analysis.
    Painschab MS; Kohler R; Kimani S; Mhango W; Kaimila B; Zuze T; Mithi V; Kasonkanji E; Mumba N; Nyasosela R; Wheeler S; Gopal S
    Lancet Glob Health; 2021 Sep; 9(9):e1305-e1313. PubMed ID: 34303416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.